title: Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.
abstract: Mycophenolate mofetil (MMF) and sirolimus (SRL) are effective immunosuppressive drugs with distinct safety profile.
  
  
  METHODS
  Kidney transplant recipients receiving tacrolimus (TAC)-based immunosuppressive regimen were randomized to receive fixed daily doses of MMF (2 g/d, n = 50) or SRL (one loading dose of 15 mg, 5 mg/d till day 7 and 2 mg/d thereafter, n = 50) without induction therapy.
  
  
  RESULTS
  No differences were observed in the incidence of the composite (biopsy-confirmed acute rejection, graft loss or death) end-point (18% vs. 16%, p = 1.000), biopsy confirmed acute rejection (12% vs. 14%, p = 1.000), one-yr patient (94% vs. 98%, p = 0.308), graft (92% vs. 98%, p = 0.168), and death-censored graft survival (98% vs. 100%, p = 0.317) comparing patients receiving MMF or SRL respectively. Patients receiving SRL showed worse safety outcomes, higher mean creatinine (1.6 +/- 0.5 mg/dL vs. 1.4 +/- 0.3 mg/dL, p = 0.007), higher proportion of patients with proteinuria (52.0% vs. 10.7%, p = 0.041), higher mean urinary protein concentrations (0.3 +/- 0.5 g/L vs. 0.1 +/- 0.2 g/L, p = 0.012), higher mean cholesterol concentration (217 mg/dL vs. 190 mg/dL, p = 0.030), and higher proportion of patients prematurely discontinued from randomized therapy (26% vs. 8%, p = 0.031).
  
  
  CONCLUSIONS
  In patients receiving TAC, MMF produced similar efficacy but superior safety profile compared with SRL.
authors.affiliation: Nephrology Division, Hospital do Rim e Hipertensão, UNIFESP, São Paulo, Brazil.
authors.forename: Edison L
authors.initials: EL
authors.lastname: Sampaio
authors.forename: Paula G
authors.initials: PG
authors.lastname: Pinheiro-Machado
authors.forename: Riberto
authors.initials: R
authors.lastname: Garcia
authors.forename: Claudia R
authors.initials: CR
authors.lastname: Felipe
authors.forename: Sung I
authors.initials: SI
authors.lastname: Park
authors.forename: Dulce E
authors.initials: DE
authors.lastname: Casarini
authors.forename: Silvia
authors.initials: S
authors.lastname: Moreira
authors.forename: Marcello F
authors.initials: MF
authors.lastname: Franco
authors.forename: Helio
authors.initials: H
authors.lastname: Tedesco-Silva
authors.forename: Jose O
authors.initials: JO
authors.lastname: Medina-Pestana
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus